The Influence Of Shenkang Injection On SOD And CRP Of CKD Patients

Objective:This paper is aim to observe the efficacy of Shenkang Injection and study its influence on SOD and CRP of patients who have chronic kidney diseasee of level 3-4 and qi of spleen and kidney deficiency with damp turbidity and blood stasis,then to discuss its possible mechanism on the relief of symptoms and delaying the progression of renal failure as well as improving renal function.Method:1.60 patients in Chinese Medicine Hospital of Hubei Province are chosen on this study. These patients all meet the standard of chronic kidney disease of level 3-4 and are diagnosed as the chronic kidney disease with qi of spleen and kidney deficiency with damp turbidity and blood stasis. They are divided into two groups randomly, the reference group(treated by Alprostadil Injection) and the treatment group(treated by Shenkang Injection), with 30 patients in each group. The source, age, sex and the course of disease of the two groups have no difference in statistical significance(P>0.05).2.Treatment: both of the two groups are given low-salt(<3g/d), quality low-protein(0.6~0.8g/kg/d), low phosphorus diet. The blood pressure, blood glucose and blood lipid are controlled. Meanwhile, treatment are applied to improve the anemia, correct the disorder of the water、electrolyte and acid-base balance, control the body infection and improve other symptoms. In addition, the reference group is given 10μg Alprostadil Injection which diluted by 0.9% sodium chloride injection 100 ml one time every day, at a speed of 20-30 drops per minute. The treatment group is given Shenkang Injection, with rhubarb、astragalus、salvia and safflower as the main composition. The Shenkang Injection is used by intravenous infusion, diluted by 150 ml 10% Glucose injection or 0.9% sodium chloride injection, with 60 ml for one time every day, at a speed of 20-30 drops per minute. The course is two weeks.3.The outcome measures:(1)Biochemical detection: before and after the treatment, the superoxide dismutase(SOD)、C-reactive protein(CRP)、serum cystatin-C(CYC)、serum creatinine(Scr)、blood urea nitrogen(BUN)、creatinine clearance(Ccr)、red blood cell count(RBC) and hemoglobin(HB) are measured.(2)The changes of TCM clinical symptom integration before and after the treatment.(3)Two weeks’ follow-up, observing the adverse reactions and the side effect.4.Statistical analysis: all the data is analyzed by medical statistics software SPSS 17.0. the experiment data is represented with( x ?s), the comparison inside the group is tested by t-method, the comparison between the groups is tested by independent sample t-method, the count data is tested by x2-method.If P<0.05 then it can be seen as having statistically difference. If P<0.01 then it has significant statistically difference. If P>0.05 then it has no statistically significance.Result:(1)Comparison of TCM clinical integration before and after the treatment: the TCM clinical integration of both groups is decreasing with significant difference(P<0.01). The treatment group is better than the reference group in TCM clinical integration as P<0.05.(2)Comparison of efficiency before and after the treatment: the total efficiency of the treatment group is 90.0%, and the reference group is 86.7%. The efficiency of the two groups have no significant difference(P>0.05).(3)Comparison of SOD、CRP before and after the treatment: the SOD、CRP of treatment group before and after the treatment have statistical significance(P<0.05);but for the reference group there are no significant difference(P>0.05). The treatment group is better than the reference group in reducing SOD、CRP as P<0.05.(4)Comparison of biochemical indicators before and after the treatment: the Cys C、BUN、Scr and Cys-C of the treatment group and the reference group are improving(P<0.05), but the two groups have no significant difference after the treatment(P>0.05).(5)Comparison of Hb、RBC before and after the treatment: the Hb and RBC of reference group before and after the treatment have no statistically difference(P>0.05); but for the treatment group there are statistical significance(P<0.05). The treatment group is better than the reference group in incerasing Hb、RBC as P<0.05.(6)No adverse reactions occurred during the treatment of the two groups.Conclusion:The Shenkang Injection can reduce the TCM clinical integration of CKD patients with Qi of spleen and kidney deficiency with damp turbidity and blood stasis of level 3~4.Also SKI can improve the biochemical indexes such as Cys C, BUN, Scr and Ccr, and increase Hb and RBC.In addision, the SOD is elevated and the CRP is reduced than before the treatment. These results prove that SKI can lighten the symptoms of CKD patients, correct the renal anemia, protect the function of kidney, delay the renal failure as well as improve the quality of life of the patients. The inhibition of oxidative stress and micro-inflammation of CKD patients may be one of the mechanisms.